Entrex Files Quarterly Report with OTC Markets, Highlighting Strategic Market Expansion
Entrex filed its quarterly report with OTC Markets, which discloses the strategic transition to a diversified network of alternative sector & regional markets.
Entrex (OTCBB:NTRX)
'Licensing our proven Entrex Capital Market platform — demonstrated through real revenues and profits — is a logical next step to scale to build and support long-term shareholder value'— Stephen H. Watkins
BOCA RATON, FL, UNITED STATES, May 14, 2025 / EINPresswire.com / -- Entrex Files Quarterly Report with OTC Markets, Highlighting Strategic Market Expansion
Entrex (OTC: NTRX) announced today the filing of its quarterly report with OTC Markets, marking the company's strategic transition from a single-sector carbon focus to a diversified network of alternative sector and regional markets. Each new market leverages Entrex's proven and regulatory-compliant technology platform designed to enable institutional and accredited investors to find, research, track, manage, and trade private securities in entrepreneurial sectors.
'With shifting cultural and policy sentiment away from ESG and environmental securities, we saw an opportunity to broaden the application of our proven platform to support institutional fixed-income investors,' said Stephen H. Watkins, CEO of Entrex. 'Our financial statements now reflect early licensing agreements and structured relationships across each emerging marketplace—illustrating the revenue potential and scalability of our model.'
Thomas Harblin, Partner at Entrex, added, 'By maintaining 51% non-dilutive ownership in each licensed market and offering an 11.6x EBITDA buyout option, we enable sector operators to grow their platforms under a known exit framework. This structure minimizes capital expenditure and operational risk for Entrex while creating compelling value opportunities for NTRX shareholders.'
Watkins continued, 'Licensing our proven Entrex Capital Market platform—demonstrated through real revenues and profits—is a logical next step. We anticipate generating scalable issuer licensing fees and recurring transaction revenues, both of which will support long-term shareholder value.'
'With 33 million private companies in the United States compared to only 18,000 publicly traded ones, the market opportunity is massive. Our goal is to provide a capital access and investment infrastructure that serves this underserved majority with proven, regulatory-compliant, and revenue-based technology.'
________________________________________
About Entrex
Entrex (OTC: NTRX) is a publicly traded company that creates regulatory-compliant marketplaces for private company securities. Its platform enables institutional and accredited investors to access fixed-income, revenue-based securities, including TIGRcubs® (Top-Line Income Generating Rights Certificates). These structured financial instruments provide non-dilutive growth capital to issuers and scalable, cash-flow-backed returns to investors.
Entrex licenses its platform to sector-specific and regional markets, each operating under a $31 million licensing agreement, with Entrex retaining a 51% equity position and a performance-based acquisition option. The company also operates the Private Company Index (PCI), which benchmarks top-line revenue performance across private enterprises.
To learn more, visit www.entrex.net
Media Contact:
Stephen H. Watkins
Chief Executive Officer
Stephen Watkins
Entrex
+1 561-465-7454
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 days ago
- Business Insider
Xiaomi (XIACF): New Buy Recommendation for This Technology Giant
In a report released yesterday, Mark Li from Bernstein maintained a Buy rating on Xiaomi (XIACF – Research Report), with a price target of HK$60.00. The company's shares closed today at $6.84. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Li is a 5-star analyst with an average return of 24.5% and a 61.19% success rate. Li covers the Technology sector, focusing on stocks such as TSMC, Micron, and United Micro. In addition to Bernstein, Xiaomi also received a Buy from Macquarie's Cherry Ma in a report issued on June 4. However, on the same day, J.P. Morgan maintained a Hold rating on Xiaomi (Other OTC: XIACF). Based on Xiaomi's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $111.29 billion and a net profit of $10.92 billion. In comparison, last year the company earned a revenue of $75.51 billion and had a net profit of $4.18 billion
Yahoo
2 days ago
- Yahoo
Analysts raise price targets on CoreWeave after blowout Q1, despite CapEx concerns
-- CoreWeave Inc (NASDAQ:CRWV) reported a strong debut earnings release as a public company, delivering better-than-expected revenue and robust guidance. Yet, shares fell by 5.4% in Thursday's trading, with investors focusing on the company's aggressive capital expenditure plans. Despite near-term pressure, analysts overwhelmingly reiterated bullish ratings and have significantly raised price targets. They cited rapid AI infrastructure demand and substantial new customer wins as the driving forces behind CoreWeave's long-term positioning. The AI-oriented cloud infrastructure firm delivered first-quarter revenue of $981.6 million, surpassing estimates by over $100 million and growing 420% year-over-year. CoreWeave expects Q2 revenue of $1.06 billion to $1.1 billion and full-year revenue between $4.9 billion and $5.1 billion, well ahead of consensus estimates. However, CapEx guidance of $3 to $3.5 billion for the second quarter, roughly three times expected revenue, led to concerns around free cash flow and dilution risk. Investors reacted negatively to the elevated spending levels despite the otherwise strong results. BofA analyst Brad Sills raised his price target to $76 from $42 while maintaining a Buy rating, calling CoreWeave's Q1 performance validation of its 'best-of-breed' position in the AI infrastructure market. Sills flagged better-than-expected return on net assets and strong contract signings, including a $12 billion OpenAI deal and $4 billion expansion with another large enterprise. While acknowledging CapEx came in above forecasts, he highlighted margin stability when adjusting for IPO-related costs. Mizuho's Gregg Moskowitz lifted his price target to $70 from $46 and reiterated an Outperform rating. He noted that the company's top-line guidance is 'materially' ahead of already strong Street expectations. 'CRWV is positioned to capture meaningful share of an AI cloud provider market growing at a server-melting pace,' Moskowitz wrote. He acknowledged near-term pressure on margins due to accelerated investment but said valuation remains reasonable. Jefferies analyst Brent Thill raised his price target to $80 from $51. He called CoreWeave a 'multi-year winner' based on customer growth and its ability to align CapEx with signed contractual deals. Thill cited new enterprise traction and the deal with OpenAI as evidence of momentum. He said the stock's premium to peers is justified by its unmatched growth profile in a rapidly scaling market. Not all analysts were bullish. Citi reiterated a Neutral rating and $43 target, pointing to mixed profitability and declining RPO. DA Davidson downgraded the stock to Underperform with a $36 target. The firm warned that investors 'may not want to scale this business,' drawing comparisons to the pitfalls of scaling WeWork (OTC:WEWKQ). Still, most analysts see CoreWeave as poised to capitalize on accelerating AI infrastructure demand. As Morgan Stanley's Keith Weiss wrote, 'Accruing large contracts from the most demanding GenAI users provides strong validation of CoreWeave's positioning.' Related articles Analysts raise price targets on CoreWeave after blowout Q1, despite CapEx concerns Constellation Brands jumps as Berkshire raises stake CrowdStrike CEO Kurtz said 'not riding off into sunset', remains large shareholder Connectez-vous pour accéder à votre portefeuille
Business Wire
2 days ago
- Business Wire
RBGLY Investors Have Opportunity to Lead Reckitt Benckiser Group plc Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Reckitt Benckiser Group plc ('Reckitt' or 'the Company') (OTC: RBGLY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 13, 2021 and July 28, 2024, inclusive (the 'Class Period'), are encouraged to contact the firm before August 4, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Reckitt failed to inform investors that preterm infants suffered an increased risk of developing necrotizing enterocolitis ('NEC') when consumed its Enfamil formula. The Company misled investors about its exposure to legal claims related to NEC. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Reckitt, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
